Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $46.67.
Several analysts recently issued reports on NBTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. Guggenheim assumed coverage on Nanobiotix in a research note on Tuesday, September 15th. They set a “buy” rating and a $64.00 price objective on the stock.
View Our Latest Report on NBTX
Nanobiotix Price Performance
Shares of NBTX stock opened at $22.23 on Friday. The company’s fifty day simple moving average is $35.01 and its 200-day simple moving average is $36.72. Nanobiotix has a 52 week low of $14.78 and a 52 week high of $57.14.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. Headquartered in France, the company uses its proprietary NanoXray technology to design nanoparticles intended to enhance the effects of radiotherapy within solid tumors.
Nanobiotix’s lead product candidate, NBTXR3, is an investigational radioenhancer composed of hafnium oxide nanoparticles. Administered directly into a tumor before radiotherapy, NBTXR3 is designed to increase energy deposition in cancer cells when exposed to X-rays, with the goal of improving tumor control while using established radiation-treatment techniques.
The company is evaluating NBTXR3 in clinical studies across several cancer indications, including locally advanced soft-tissue sarcoma and head and neck cancers, as well as other solid tumors.
Read More
- Five stocks we like better than Nanobiotix
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
